Benzinga
Benzinga
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Benzinga
viernes, noviembre 06
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Arvinas Inc
ARVN
NASDAQ
Lista de seguimiento
Get Report
Trade with Public
Get Report
Trade with Public
$6.55
-0.87
-11.73%
Últ. Act.: Nov 6, 4:00 AM
Get Report
Panorámica general
Noticias
Previsión de beneficios
Eventos
Precios objetivo
Finanzas
Sentimiento
Propiedad
Comparar
Opciones
Informe de acciones
Ganancias:
Los beneficios de Q3 2026 se publicaron el mar nov 3rd, antes de la apertura del mercado
Conferencia telefónica:
La conferencia telefónica más reciente comenzó a las 8:00 a. m., hace 3 días
Haz clic para ver el webcast
Arvinas Financials
Arvinas (ARVN) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Arvinas Says Cash, Cash Equivalents, Restricted Cash, and Marketable Securities of $558.9M As of September 30, 2026, is Expected to Provide Cash Runway into 2H 2028
Benzinga Newsdesk
PRO
Arvinas Q3 EPS $(0.82) Beats $(0.83) Estimate, Sales $500.000K May Not Be Comparable To $22.490M Estimate
Benzinga Newsdesk
PRO
Arvinas Q2 EPS $2.58 Beats $(0.44) Estimate, Sales $249.700M Beat $32.542M Estimate
Arvinas (NASDAQ:ARVN) reported quarterly earnings of $2.58 per share which beat the analyst consensus estimate of $(0.44) by 686.36 percent. This is a 407.14 percent increase over losses of $(0.84) per share from the
Benzinga Newsdesk
PRO
Arvinas Announces Re-Prioritization Of Portfolio Following Strategic Review; Plans To Complete Phase 1 Monotherapy Dose Escalation Trial And Share Data In 2026; Plans To Seek Out-Licensing Agreement For Additional Clinical Trials Of ARV-806; Expects Cash Position As Of March 31, 2026 To Fund Operations Into Second Half Of 2028
Following a strategic review of its pipeline, the Company has made the decision to re-prioritize its portfolio. As previously disclosed, in the second quarter of 2026, the Company announced that it had completed dose
Benzinga Newsdesk
These Analysts Increase Their Forecasts On Arvinas After Q1 Results
Arvinas Inc (NASDAQ:ARVN) reported Q1 losses of 90 cents/share, missed analyst estimates. Rigel Pharmaceuticals (NASDAQ:RIGL) announced global licensing agreement with Arvinas and Pfizer (NYSE:PFE) for oral PROTAC drug VEPPANU. Arvinas shares rose 1.7% on Wednesday and analysts have raised price targets.
Avi Kapoor
Earnings Scheduled For May 12, 2026
Benzinga Insights
